文献速递肝病消化道肿瘤与早癌

PARG抑制限制肝细胞癌进展并增强免疫检查点治疗疗效

PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
PubMed 文献 · J Hepatol · 2022-02-12

该研究探讨PARG在肝细胞癌中的病理生理作用及靶向去PAR化治疗的价值。在两种原位异种移植模型和Pargflox/flox小鼠模型中评估PARG的致癌功能,并在小鼠原位模型中评估PARG抑制剂联合抗PD-1抗体的疗效。结果显示高PARG表达与HCC预后不良强相关,肝细胞特异性PARG缺失显著削弱肝脏肿瘤发生;PARG通过DDB1依赖性调控c-Myc促进HCC生长和转移,PARG抑制剂与抗PD-1抗体在原位小鼠模型中可协同作用。

要点

  • 高PARG表达与肝细胞癌预后不良强相关,肝细胞特异性PARG缺失显著削弱肝脏肿瘤发生。
  • PARG通过去PAR化DDB1促进其自身泛素化,从而稳定c-Myc蛋白,促进HCC生长和转移。
  • PARG抑制剂与抗PD-1抗体在原位小鼠模型中可协同作用,PARG下调与接受抗PD-1免疫治疗患者的良好预后相关。

核心结论

  • PARG通过调控PARG/DDB1/c-Myc信号在HCC中发挥致癌基因作用,并可作为生物标志物识别可能从抗PD-1治疗中获益的HCC患者。
  • 研究结果提示,同时抑制PARG和PD-1是HCC患者有效的新型联合策略。

研究设计与样本

  • 研究在2种原位异种移植模型和Pargflox/flox小鼠模型中评估PARG的致癌功能。
  • 在小鼠原位模型中评估PARG抑制剂联合抗PD-1抗体的治疗疗效。
  • 采用微阵列分析评估PARG/DDB1/c-Myc/MMR轴的病理相关性。

主要发现

  • 高PARG表达与HCC预后不良强相关,肝细胞特异性PARG缺失显著削弱肝脏肿瘤发生。
  • PARG通过DDB1依赖性调控c-Myc促进HCC生长和转移。
  • PARG去PAR化DDB1并促进DDB1自身泛素化,从而稳定HCC细胞中的c-Myc蛋白。
  • PARG下调减弱c-Myc诱导的MMR表达,PARG缺陷与接受抗PD-1为基础免疫治疗的HCC患者良好预后相关。
  • PARG抑制剂与抗PD-1抗体在原位小鼠模型中可协同作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although the treatment of hepatocellular carcinoma (HCC) has been revolutionized by the advent of effective systemic therapies, the prognosis of patients with HCC remains dismal. Herein, we examined the pathophysiological role of PARG and assessed the utility of targeting dePARylation for HCC therapy. METHODS: The oncogenic function of PARG was evaluated in 2 orthotopic xenograft models and a Pargflox/flox mice model. The therapeutic efficacy of PARG inhibitors in combination with an anti-PD-1 antibody were assessed in murine orthotopic models. Microarray analysis was used to evaluate the pathological relevance of the PARG/DDB1/c-Myc/MMR axis. RESULTS: High PARG expression was strongly associated with poor HCC prognosis. Hepatocyte-specific PARG deletion significantly impaired liver tumorigenesis. PARG promoted HCC growth and metastasis through DDB1-dependent modulation of c-Myc. Specifically, PARG dePARylated DDB1 and consequently promoted DDB1 autoubiquitination, thus stabilizing the c-Myc protein in HCC cells. PARG downregulation attenuated c-Myc-induced MMR expression and PARG deficiency was correlated with a favorable prognosis in patients with HCC treated with anti-PD-1-based immunotherapy. In addition, PARG inhibitors could act in synergy with anti-PD-1 antibodies in orthotopic mouse models. CONCLUSIONS: PARG can act as an oncogene in HCC by modulating PARG/DDB1/c-Myc signaling and could be used as a biomarker to identify patients with HCC who may benefit from anti-PD-1 treatment. Our findings suggest that co-inhibition of PARG and PD-1 is an effective novel combination strategy for patients with HCC. LAY SUMMARY: The increase in deaths due to hepatocellular carcinoma (HCC) is a growing concern, with the mechanisms responsible for HCC development still incompletely understood. Herein, we identify a novel mechanism by which the protein PARG contributes to HCC development. Inhibition of PARG increased the efficacy of anti-PD-1 therapy (a type of immunotherapy) in HCC. These findings support the future clinical development of PARG inhibitors, potentially in combination with anti-PD-1 inhibitors.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yu M, Chen Z, Zhou Q, et al. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. J Hepatol. 2022. PMID: 35157958. doi:10.1016/j.jhep.2022.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。